Oral membrane-biomimetic nanoparticles for enhanced endocytosis and regulation of tumor-associated macrophage

J Nanobiotechnology. 2023 Jul 4;21(1):206. doi: 10.1186/s12951-023-01949-5.

Abstract

Enterocyte uptake with high binding efficiency and minor endogenous interference remains a challenge in oral nanocarrier delivery. Enterocyte membrane-biomimetic lipids may universally cooperate with endogenous phosphatidyl choline via a biorthogonal group. In this study, we developed a sophorolipid-associated membrane-biomimetic choline phosphate-poly(lactic-co-glycolic) acid hybrid nanoparticle (SDPN). Aided by physical stability in the gastrointestinal tract and rapid mucus diffusion provided by association with sophorolipid, these nanoparticles show improved endocytosis, driven by dipalmitoyl choline phosphate-phosphatidyl choline interaction as well as its optimized membrane fluidity and rigidity. Luteolin- and silibinin-co-loaded with SDPN alleviated breast cancer metastasis in 4T1 tumor-bearing mice by regulating the conversion of tumor-associated M2 macrophages into the M1 phenotype and reducing the proportion of the M2-phenotype through co-action on STAT3 and HIF-1α. In addition, SDPN reduces angiogenesis and regulates the matrix barrier in the tumor microenvironment. In conclusion, this membrane-biomimetic strategy is promising for improving the enterocyte uptake of oral SDPN and shows potential to alleviate breast cancer metastasis.

Keywords: Enterocyte uptake; Membrane-biomimetic; Overcoming intestinal barriers; Regulation of tumor-associated macrophage.

MeSH terms

  • Animals
  • Biomimetics
  • Cell Line, Tumor
  • Mice
  • Nanoparticles*
  • Neoplasms*
  • Phosphorylcholine
  • Tumor Microenvironment
  • Tumor-Associated Macrophages

Substances

  • Phosphorylcholine